TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE

Aim. To study the influence of metabolic cytoprotector trimetazidine on the heart rate variability (HRV) in patients with stable ischemic heart disease (CHD).Material and methods. Into the simple, prospective, non-randomized trial totally 50 patients included with stable CHD, continuously showed pos...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Novikova, M. G. Glezer
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2014-10-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/53
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849250281056894976
author M. V. Novikova
M. G. Glezer
author_facet M. V. Novikova
M. G. Glezer
author_sort M. V. Novikova
collection DOAJ
description Aim. To study the influence of metabolic cytoprotector trimetazidine on the heart rate variability (HRV) in patients with stable ischemic heart disease (CHD).Material and methods. Into the simple, prospective, non-randomized trial totally 50 patients included with stable CHD, continuously showed positive stress test on treadmill. HRV was investigated on the short episodes of recording (the device and software of MEDASS, Russia) before and after 4-month therapy by trimetazidine 35 mg BID in supine position and during the 10-minute active ortostatic test. The temporal and frequency parameters of HRV were assessed.Results. HRV in CHD patients is decreased and the prominence of the decrease depends upon gender, age, diabetes mellitus and ejection fraction. After the shift from supine to upright position with normal reaction of heartrate there was decrease of RR-interval moda and normalized value in the area of high-frequency component, the vegetative balance index increased, as the centralization index, that shows on the decrease of parasympathetic influence. While being treated by trimetazidine the HRV parameters were increased in the temporal area – variational amplitude between maximal and minimal values, also there was decrease (improvement) of vegetative balance index and index of regulatory systems tension.Conclusion. Trimetazidine in patients with stable CHD increases the decreased at baseline HRV and normalizes the reaction on ortostatic test. Its effects can be explained by the decrease of ischemia, oxidative stress and improvement of nitric oxide bioavailability.
format Article
id doaj-art-21e0fcf9956f4cecbd0be5166b713ec2
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2014-10-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-21e0fcf9956f4cecbd0be5166b713ec22025-08-20T03:57:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252014-10-01135364410.15829/1728-8800-2014-5-36-4453TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASEM. V. Novikova0M. G. Glezer1SBHI City Clinical Hospital №59, MoscowSBEI HPE First Moscow State Medical University n. a. Sechenov I. M. of the Ministry of Health, MoscowAim. To study the influence of metabolic cytoprotector trimetazidine on the heart rate variability (HRV) in patients with stable ischemic heart disease (CHD).Material and methods. Into the simple, prospective, non-randomized trial totally 50 patients included with stable CHD, continuously showed positive stress test on treadmill. HRV was investigated on the short episodes of recording (the device and software of MEDASS, Russia) before and after 4-month therapy by trimetazidine 35 mg BID in supine position and during the 10-minute active ortostatic test. The temporal and frequency parameters of HRV were assessed.Results. HRV in CHD patients is decreased and the prominence of the decrease depends upon gender, age, diabetes mellitus and ejection fraction. After the shift from supine to upright position with normal reaction of heartrate there was decrease of RR-interval moda and normalized value in the area of high-frequency component, the vegetative balance index increased, as the centralization index, that shows on the decrease of parasympathetic influence. While being treated by trimetazidine the HRV parameters were increased in the temporal area – variational amplitude between maximal and minimal values, also there was decrease (improvement) of vegetative balance index and index of regulatory systems tension.Conclusion. Trimetazidine in patients with stable CHD increases the decreased at baseline HRV and normalizes the reaction on ortostatic test. Its effects can be explained by the decrease of ischemia, oxidative stress and improvement of nitric oxide bioavailability.https://cardiovascular.elpub.ru/jour/article/view/53stable angina heart rate variabilityortostatic testtrimetazidine
spellingShingle M. V. Novikova
M. G. Glezer
TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
Кардиоваскулярная терапия и профилактика
stable angina heart rate variability
ortostatic test
trimetazidine
title TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
title_full TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
title_fullStr TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
title_full_unstemmed TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
title_short TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
title_sort trimetazidine therapy influence on heart rate variability in patients with stable ischemic heart disease
topic stable angina heart rate variability
ortostatic test
trimetazidine
url https://cardiovascular.elpub.ru/jour/article/view/53
work_keys_str_mv AT mvnovikova trimetazidinetherapyinfluenceonheartratevariabilityinpatientswithstableischemicheartdisease
AT mgglezer trimetazidinetherapyinfluenceonheartratevariabilityinpatientswithstableischemicheartdisease